Steven C. Hoffmann

984 total citations
11 papers, 676 citations indexed

About

Steven C. Hoffmann is a scholar working on Immunology, Economics and Econometrics and Pharmacology. According to data from OpenAlex, Steven C. Hoffmann has authored 11 papers receiving a total of 676 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Immunology, 3 papers in Economics and Econometrics and 2 papers in Pharmacology. Recurrent topics in Steven C. Hoffmann's work include Health Systems, Economic Evaluations, Quality of Life (3 papers), Biosimilars and Bioanalytical Methods (3 papers) and Biomedical and Engineering Education (2 papers). Steven C. Hoffmann is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (3 papers), Biosimilars and Bioanalytical Methods (3 papers) and Biomedical and Engineering Education (2 papers). Steven C. Hoffmann collaborates with scholars based in United States, Australia and Switzerland. Steven C. Hoffmann's co-authors include Virginia B. Kraus, David J. Hunter, Jamie E. Collins, Allan D. Kirk, Linda J. Sandell, Michael C. Nevitt, Elena Losina, Jeffrey N. Katz, James L. Riley and Patrick J. Blair and has published in prestigious journals such as The Journal of Experimental Medicine, SHILAP Revista de lepidopterología and Nature Reviews Drug Discovery.

In The Last Decade

Steven C. Hoffmann

11 papers receiving 660 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Steven C. Hoffmann United States	9	210	181	154	114	102	11	676
Roberto Díaz‐Peña Spain	19	227 1.1×	365 2.0×	41 0.3×	221 1.9×	23 0.2×	73	972
Yang Jun China	12	34 0.2×	302 1.7×	73 0.5×	69 0.6×	78 0.8×	18	605
D. Adorno Italy	11	28 0.1×	174 1.0×	104 0.7×	48 0.4×	131 1.3×	73	432
Hillary Johnston‐Cox United States	12	45 0.2×	43 0.2×	113 0.7×	208 1.8×	9 0.1×	16	818
B. Schlüter Germany	13	80 0.4×	116 0.6×	59 0.4×	118 1.0×	8 0.1×	46	471
Caleb Cornaby United States	12	208 1.0×	236 1.3×	22 0.1×	88 0.8×	15 0.1×	25	535
S. Jacobs United States	23	109 0.5×	18 0.1×	223 1.4×	152 1.3×	43 0.4×	46	1.3k
Sanketh Rampes United Kingdom	10	89 0.4×	41 0.2×	89 0.6×	52 0.5×	6 0.1×	16	408
Fabio Basta Italy	12	352 1.7×	279 1.5×	37 0.2×	85 0.7×	3 0.0×	33	612

Countries citing papers authored by Steven C. Hoffmann

Since Specialization

Citations

This map shows the geographic impact of Steven C. Hoffmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven C. Hoffmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven C. Hoffmann more than expected).

Fields of papers citing papers by Steven C. Hoffmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven C. Hoffmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven C. Hoffmann. The network helps show where Steven C. Hoffmann may publish in the future.

Co-authorship network of co-authors of Steven C. Hoffmann

This figure shows the co-authorship network connecting the top 25 collaborators of Steven C. Hoffmann. A scholar is included among the top collaborators of Steven C. Hoffmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven C. Hoffmann. Steven C. Hoffmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Bakker, Jessie P., et al.. (2024). Regulatory Pathways for Qualification and Acceptance of Digital Health Technology‐Derived Clinical Trial Endpoints: Considerations for Sponsors. Clinical Pharmacology & Therapeutics. 117(1). 56–72. 6 indexed citations

Hunter, David J., Jamie E. Collins, Leticia A. Deveza, Steven C. Hoffmann, & Virginia B. Kraus. (2023). Biomarkers in osteoarthritis: current status and outlook — the FNIH Biomarkers Consortium PROGRESS OA study. Skeletal Radiology. 52(11). 2323–2339. 21 indexed citations

Izmailova, Elena S., William A. Wood, Qi Liu, et al.. (2021). Remote Cardiac Safety Monitoring through the Lens of the FDA Biomarker Qualification Evidentiary Criteria Framework: A Case Study Analysis. SHILAP Revista de lepidopterología. 5(1). 103–113. 7 indexed citations

Porter, Amy C., Jiri Aubrecht, Jonathan Braun, et al.. (2020). Biomarkers of Crohn’s Disease to Support the Development of New Therapeutic Interventions. Inflammatory Bowel Diseases. 26(10). 1498–1508. 14 indexed citations

Goldsack, Jennifer C., Elena S. Izmailova, Joseph P. Menetski, et al.. (2020). Remote digital monitoring in clinical trials in the time of COVID-19. Nature Reviews Drug Discovery. 19(6). 378–379. 22 indexed citations

Menetski, Joseph P., Steven C. Hoffmann, Stephanie S. Cush, et al.. (2019). The Foundation for the National Institutes of Health Biomarkers Consortium: Past Accomplishments and New Strategic Direction. Clinical Pharmacology & Therapeutics. 105(4). 829–843. 31 indexed citations

Kraus, Virginia B., Jamie E. Collins, Elena Losina, et al.. (2016). Predictive validity of biochemical biomarkers in knee osteoarthritis: data from the FNIH OA Biomarkers Consortium. Annals of the Rheumatic Diseases. 76(1). 186–195. 199 indexed citations

Talbot, George H., et al.. (2015). Developing Outcomes Assessments as Endpoints for Registrational Clinical Trials of Antibacterial Drugs: 2015 Update From the Biomarkers Consortium of the Foundation for the National Institutes of Health: Table 1.. Clinical Infectious Diseases. 62(5). 603–607. 27 indexed citations

Spellman, Daniel S., Kristin R. Wildsmith, Lee Honigberg, et al.. (2015). Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF. PROTEOMICS - CLINICAL APPLICATIONS. 9(7-8). 715–731. 106 indexed citations

10.

Kirk, Allan D., Roslyn B. Mannon, David E. Kleiner, et al.. (2005). Results from a Human Renal Allograft Tolerance Trial Evaluating T-Cell Depletion with Alemtuzumab Combined with Deoxyspergualin. Transplantation. 80(8). 1051–1059. 91 indexed citations

11.

Blair, Patrick J., James L. Riley, David M. Harlan, et al.. (2000). Cd40 Ligand (Cd154) Triggers a Short-Term Cd4+ T Cell Activation Response That Results in Secretion of Immunomodulatory Cytokines and Apoptosis. The Journal of Experimental Medicine. 191(4). 651–660. 152 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact